Low dose combinations of 2-methoxyestradiol and docetaxel block prostate cancer cells in mitosis and increase apoptosis

Cancer Letters

Volumn 276, Issue 1, 2009, Pages 21-31

  Reiner, Teresita ^b   Pozas, Alicia de las ^a   Gomez, Lourdes A ^d   Perez Stable, Carlos ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d South Florida Veterans Affairs Foundation   (United States)

Author keywords

Apoptosis; Cell cycle arrest; Chemotherapy; Cyclin B1; Prostate cancer

Indexed keywords

2 METHOXYESTRADIOL; ANDROGEN; CYCLIN A; CYCLIN DEPENDENT KINASE; DOCETAXEL; ESTRADIOL; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL GROWTH; COMPETITIVE INHIBITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MEGADOSE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; METABOLITE; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; ESTRADIOL; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, TRANSGENIC; MITOSIS; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; TAXOIDS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; MUS MUSCULUS;

EID: 60249092333     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.10.026     Document Type: Article

References (53)

1. Tannock I.F., De Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., Oudard S., Theodore C., James N.D., Turesson I., Rosenthal M.A., and Eisenberger M.A. TAX 327 Investigators, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351 (2004) 1502-1512
2. Available from: .
3. Petrylak D.P. The treatment of hormone-refractory prostate cancer Docetaxel and beyond. Rev. Urol. 8 Suppl. 2 (2006) S48-S55
4. Pribluda V.S., Gubish E.R., LaValle T.M., Treston A., Swartz G.M., and Green S.J. 2-methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Met. Rev. 19 (2000) 173-179
5. Mooberry S.L. New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Curr. Opin. Oncol. 15 (2003) 425-430
6. LaVallee T.M., Zhan X.H., Herbstritt C.J., Kough E.C., Green S.J., and Pribluda V.S. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors α and β. Cancer Res. 62 (2002) 3691-3697
7. DeVoogt H.J., Smith P.H., Pavone-Macaluso M., De Pauw M., and Suciu S. Cardiovascular side effects of diethylstilbesterol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostate cancer: results from European Organization for Research on Treatment of Cancer Trials 30761 and 30762. J. Urol. 135 (1986) 303-307
8. Banerjee S.N., Sengupta K., Banerjee S., Saxena N.K., and Banerjee S.K. 2-Methoxyestradiol exhibits a biphasic effect on VEGF-A in tumor cells and upregulation is mediated through ER-alpha: a possible signaling pathway associated with the impact of 2-ME2 on proliferative cells. Neoplasia 5 (2003) 417-426
9. Liu Z.J., and Zhu B.T. Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells. J. Steroid Biochem. Mol. Biol. 88 (2004) 265-275
10. Herbst R.S., and Khuri F.R. Mode of action of docetaxel - a basis for combination with novel anticancer agents. Cancer Treat. Rev. 29 (2003) 407-415
11. Qadan L.R., Perez-Stable C.M., Anderson C., D'Ippolito G., Herron A., Howard G.A., and Roos B.A. 2-Methoxyestradiol induces G2/M arrest and apoptosis in prostate cancer. Biochem. Biophys. Res. Commun. 285 (2001) 1259-1266
12. Perez-Stable C. 2-Methoxyestradiol and paclitaxel have similar effects on the cell cycle and induction of apoptosis in prostate cancer cells. Cancer Lett. 231 (2006) 49-64
13. Gomez L.A., De las Pozas A., and Perez-Stable C. Sequential combination of flavopiridol and docetaxel reduces the levels of XIAP and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells. Mol. Cancer Ther. 5 (2006) 1216-1226
14. Nimmanapalli R., Perkins C.L., Orlando M., O'Bryan E., Nguyen D., and Bhalla K.N. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. 61 (2001) 759-763
15. Kumar A.P., Garcia G.E., Orsborn J., Levin V.A., and Slaga T.J. 2-Methoxyestradiol interferes with NF kappa B transcriptional activity in primitive neuroectodermal brain tumors: implications for management. Carcinogenesis 24 (2003) 209-216
16. Shimada K., Nakamura M., Ishida E., Kishi M., and Konishi N. Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis. Carcinogenesis 24 (2003) 1067-1075
17. LaVallee T.M., Zhan X.H., Johnson M.S., Herbstritt C.J., Swartz G., Williams M.S., Hembrough W.A., Green S.J., and Pribluda V.S. 2-Methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res. 63 (2003) 468-475
18. Zhang H., Morisaki T., Nakahara C., Matsunaga H., Sato N., Nagumo F., Tadano J., and Katano M. PSK-mediated NF-kappaB inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1. Oncogene 22 (2003) 2088-2096
19. Shimada K., Nakamura M., Ishida E., Kishi M., Matsuyoshi S., and Konishi N. The molecular mechanism of sensitization to Fas-mediated apoptosis by 2-methoxyestradiol in PC3 prostate cancer cells. Mol. Carcinog. 39 (2004) 1-9
20. Wang Q., and Wieder R. All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells. Oncogene 23 (2004) 426-433
21. Davis D.W., Buchholz T.A., Hess K.R., Sahin A.A., Valero V., and McConkey D.J. Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Clin. Cancer Res. 9 (2003) 955-960
22. Wilson L., and Jordan M.A. New microtubule/tubulin-targeted anticancer drugs and novel chemotherapeutic strategies. J. Chemother. 16 Suppl. 4 (2004) 83-85
23. Giannakakou P., Gussio R., Nogales E., Downing K.H., Zaharevitz D., Bollbuck B., Poy G., Sackett D., Nicolaou K.C., and Fojo T. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc. Natl. Acad. Sci. USA 97 (2000) 2904-2909
24. Gökmen-Polar Y., Escuin D., Walls C.D., Soule S.E., Wang Y., Sanders K.L., LaValle T.M., Wang M., Guenther B.D., Giannakakou P., and Sledge G.W. Beta-tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells. Cancer Res. 65 (2005) 9406-9414
25. Mueck A.O., Seeger H., and Huober J. Chemotherapy of breast cancer-additive anticancerogenic effects by 2-methoxyestradiol?. Life Sci. 75 (2004) 1205-1210
26. Han G.Z., Liu Z.J., Shimoi K., and Zhu B.T. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer. Cancer Res. 65 (2005) 387-393
27. James J., Murry D.J., Treston A.M., Storniolo A.M., Sledge G.W., Sidor C., and Miller K.D. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest. New Drugs 25 (2007) 41-48
28. Sweeney C., Liu G., Yiannoutsos C., Kolesar J., Horvath D., Staab M.J., Fife K., Armstrong V., Treston A., Sidor C., and Wilding G. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin. Cancer Res. 11 (2005) 6625-6633
29. Lavallee T.M., Burke P.A., Swartz G.M., Hamel E., Agoston G.E., Shah J., Suwandi L., Hanson A.D., Fogler W.E., Sidor C.F., and Treston A.M. Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198. Mol. Cancer Ther. 7 (2008) 1472-1482
30. Perez-Stable C., Altman N.H., Brown J., Cray C., Harbison M., and Roos B.A. Prostate, adrenocortical, and brown adipose tumors in fetal globin/T antigen transgenic mice. Lab. Invest. 74 (1996) 363-373
31. Perez-Stable C., Altman N.H., Mehta P.P., Deftos L.J., and Roos B.A. Prostate cancer progression, metastasis, and gene expression in transgenic mice. Cancer Res. 57 (1997) 900-906
32. Reiner T., de las Pozas A., Parrondo R., and Perez-Stable C. Progression of prostate cancer from a subset of p63 positive basal epithelial cells in FG/Tag transgenic mice. Mol. Cancer Res. 5 (2007) 1171-1179
33. Perez-Stable C.M., Schwartz G.G., Farinas A., Finegold M., Binderup L., Howard G.A., and Roos B.A. The Gγ/T-15 transgenic mouse model of androgen-independent prostate cancer: target cells of carcinogenesis, the effect of the vitamin D analog EB 1089. Cancer Epi Biol. Prev. 11 (2002) 555-563
34. Reiner T., de las Pozas A., and Perez-Stable C. Sequential combinations of flavopiridol and docetaxel inhibit prostate tumors, induce apoptosis, and decreases angiogenesis in the Ggamma/T-15 transgenic mouse model of prostate cancer. Prostate 66 (2006) 1487-1497
35. van Bokhoven A., Varella-Garcia M., Korch C., Johannes W.U., Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., and Lucia M.S. Molecular characterization of human prostate carcinoma cell lines. Prostate 57 (2003) 205-225
36. Dai J.L., Maiorino C.A., Gkonos P.J., and Burnstein K.L. Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells. Steroids 61 (1996) 531-539
37. Gomez L.A., de las Pozas A., Reiner T., Burnstein K., and Perez-Stable C. Increased expression of cyclin B1 tumor-specific antigen sensitizes prostate cancer cells to apoptosis induced by chemotherapy. Mol. Cancer Ther. 6 (2007) 1534-1543
38. Krishan A. Rapid DNA content analysis by the propidium iodide-hypotonic citrate method. Methods Cell Biol. 33 (1990) 121-125
39. Slingerland J.M., Jenkins J.R., and Benchimol S. The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation Oligomerization and nuclear translocation. EMBO J. 12 (1993) 1029-1037
40. Auffray C., and Rougeon F. Purification of mouse immunoglobulin heavy chain messenger RNAs from total myeloma tumor DNA. Eur. J. Biochem. 107 (1980) 303-314
41. Kumar A.P., Garcia G.E., and Slaga T.J. 2-Methoxyestradiol blocks cell-cycle progression at G(2)/M phase and inhibits growth of human prostate cancer cells. Mol. Carcinog. 31 (2001) 111-124
42. Ray G., Dhar G., Van Veldhuizen P.J., Banerjee S., Saxena N.K., Sengupta K., and Banerjee S.K. Modulation of cell-cycle regulatory signaling network by 2-methoxyestradiol in prostate cancer cells is mediated through multiple signal transduction pathways. Biochemistry 45 (2006) 3703-3713
43. Mashal R.D., Lester S., Corless C., Richie J.P., Chandra R., Propert K.J., and Dutta A. Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res. 56 (1996) 4159-4163
44. Kawamoto H., Koizumi H., and Uchikoshi T. Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions: immunocytochemical and quantitative image analyses. Am. J. Pathol. 150 (1997) 15-23
45. Kao H., Marto J.A., Hoffmann T.K., Shabanowitz J., Finkelstein S.D., Whiteside T.L., Hunt D.F., and Finn O.J. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J. Exp. Med. 194 (2001) 1313-1323
46. Mendiratta P., Armstrong A.J., and George D.J. Current standard and investigational approaches to the management of hormone-refractory prostate cancer. Rev. Urol. 9 Suppl. 1 (2007) S9-S19
47. Kamath K., Okouneva T., Larson G., Panda D., Wilson L., and Jordan M.A. 2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules. Mol. Cancer Ther. 5 (2006) 2225-2233
48. Castedo M., Perfettini J.L., Roumier T., Andreau K., Medema R., and Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 23 (2004) 2825-2837
49. Chen W., Lee J., Cho S.Y., and Fine H.A. Proteasome-mediated destruction of the cyclin a/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo. Cancer Res. 64 (2004) 3949-3957
50. Ando T., Kawabe T., Ohara H., Ducommun B., Itoh M., and Okamoto T. Involvement of the interaction between p21 and proliferating cell nuclear antigen for the maintenance of G2/M arrest after DNA damage. J. Biol. Chem. 276 (2001) 42971-42977
51. Jänicke R.U., Sohn D., Essmann F., and Schulze-Osthoff K. The multiple battles fought by anti-apoptotic p21. Cell Cycle 6 (2007) 407-413
52. Berges R.R., Vukanovic J., Epstein J.I., CarMichel M., Cisek L., Johnson D.E., Veltri R.W., Walsh P.C., and Isaacs J.T. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin. Cancer Res. 1 (1995) 473-480
53. Deeb K.K., Michalowska A.M., Yoon C.Y., Krummey S.M., Hoenerhoff M.J., Kavanaugh C., Li M.C., Demayo F.K., Linnoila I., Deng C.X., Lee E.Y., Medina D., Shih J.H., and Green J.E. Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis. Cancer Res. 67 (2007) 8065-8080